^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Ibrutinib and acalabrutinib ± obinutuzumab are the preferred first-line therapy options for all patients including in high-risk subgroups such as those with del(11q) or del(17p)/TP53 mutation and unmutated IGHV.
Source:
Title:
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Excerpt:
The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91%...long‐term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL...
DOI:
10.1002/ajh.25638
Trial ID:
